What is the clinical significance of an ADAMTS13 activity level of 23 % and what management is recommended?

ADAMTS13 Activity Level of 23%: Clinical Significance and Management

An ADAMTS13 activity level of 23% does NOT meet the diagnostic threshold for thrombotic thrombocytopenic purpura (TTP) and does not require TTP-specific treatment, but warrants careful clinical correlation to exclude other thrombotic microangiopathies and consideration of the patient's overall clinical context.

Diagnostic Interpretation

The 2025 ISTH guidelines clearly establish that TTP diagnosis requires ADAMTS13 activity <10% (or <10 IU/dL) 1. Your patient's level of 23% falls well above this threshold and is classified as "no deficiency" in the standard categorization scheme used in clinical practice 2.

Key Diagnostic Thresholds:

• <10%: Severe deficiency → TTP diagnosis
• 10-20%: Borderline activity → uncertain significance
• >20%: No deficiency → TTP excluded

At 23%, this patient does not have the severe ADAMTS13 deficiency that characterizes TTP 1.

Clinical Significance

What This Level Means:

Moderate ADAMTS13 deficiency (11-40% activity) has been associated with:

• Increased disease acuity markers (higher bilirubin, INR)
• Greater frequency of sepsis, shock, or multiorgan failure
• Increased 90-day mortality in univariate analysis
• However, ADAMTS13 level itself is NOT an independent predictor of mortality 2

The moderate deficiency appears to be a marker of disease severity rather than a causative factor in non-TTP thrombotic microangiopathies 2.

What to Look For Clinically:

If your patient presents with thrombocytopenia and microangiopathic hemolytic anemia despite ADAMTS13 of 23%, you must actively search for:

1. Sepsis or systemic infection (most common cause)
2. Malignancy-associated TMA
3. Drug-induced TMA (chemotherapy, immunosuppressants, quinine)
4. Pregnancy-related complications (HELLP, preeclampsia)
5. Transplant-associated TMA
6. Complement-mediated TMA (atypical HUS)
7. Malignant hypertension
8. Autoimmune disease-related TMA

In one large retrospective study, primary TMA occurred in only 6% of cases, with 94% being secondary to other conditions 3.

Management Recommendations

Immediate Actions:

Do NOT initiate TTP-specific therapy (therapeutic plasma exchange, caplacizumab, rituximab) based on this ADAMTS13 level alone 1.

Algorithmic Approach:

Step 1: Assess for TMA Syndrome

• Thrombocytopenia present? (platelets typically <30 × 10⁹/L in TTP)
• MAHA present? (schistocytes, elevated LDH, low haptoglobin, elevated indirect bilirubin)
• Organ dysfunction present? (renal, neurologic, cardiac)

Step 2: If TMA Present with ADAMTS13 23%

• Identify and treat the underlying cause (this is your primary therapeutic target)
• Check complement studies (C3, C4, CH50) if considering atypical HUS
• Review medication list for TMA-inducing drugs
• Evaluate for infection, malignancy, pregnancy complications
• Assess for malignant hypertension

Step 3: Supportive Management

• Transfuse platelets only if active bleeding or invasive procedure needed
• Manage hypertension aggressively if present
• Treat underlying infection
• Discontinue offending medications
• Consider complement blockade (eculizumab) if atypical HUS suspected

Step 4: Monitor ADAMTS13 Activity

• Repeat testing is generally NOT indicated unless clinical picture changes dramatically
• If ADAMTS13 drops to <10% on repeat testing with appropriate clinical context, reconsider TTP diagnosis

Critical Pitfalls to Avoid

1. Do not treat as TTP based on clinical presentation alone when ADAMTS13 is >10%. The 2025 guidelines emphasize that severe ADAMTS13 deficiency (<10%) is mandatory for TTP diagnosis 1.

2. Do not ignore the clinical context. While 23% excludes TTP, the patient may still have a serious thrombotic microangiopathy requiring urgent treatment of the underlying cause 2.

3. Do not assume ADAMTS13 of 23% is "protective". This level can still be associated with worse outcomes in the context of sepsis, multiorgan failure, or other acute illnesses, though it reflects disease severity rather than being causative 2.

4. Do not delay treatment of the actual underlying condition while focusing on the ADAMTS13 result. The turnaround time for ADAMTS13 testing averages 2-4 days, and clinical decisions must be made based on the complete picture 4, 5.

Prognostic Considerations

Independent predictors of 90-day mortality in patients with TMA and ADAMTS13 >10% include 2:

• Charlson comorbidity index
• Elevated ALT
• Low platelet count
• Elevated creatinine
• Presence of sepsis, shock, or multiorgan failure

The ADAMTS13 level of 23% itself does not independently predict mortality but signals the need for aggressive management of these other factors 2.

Follow-Up

• No routine ADAMTS13 monitoring is needed if TMA resolves with treatment of underlying cause
• If patient has recurrent TMA episodes, consider repeat ADAMTS13 testing during acute episodes
• Document this result for future reference if patient presents with similar symptoms